0:00
welcome back to health awareness your go
0:02
to channel for the latest updates in
0:04
medical research and health Innovations
0:06
today we're diving into an exciting
0:08
development in the quest to cure
0:10
HIV according to CEO Jeff Galvin the
0:14
cell and gene therapy developer hopes
0:16
its ad immune spinout will pick up where
0:18
American Gene Technologies AGT leaves
0:21
off in developing a one-time treatment
0:23
for HIV in light of positive early data
0:26
a leading developer of Gene and cell
0:28
therapies is spinning out a new company
0:31
focused on bringing to Market Curative
0:33
Gene and cell treatments for HIV
0:35
starting with its phase IV starting with
0:37
its phasi completed one and done
0:40
autologous it cell therapy for the AIDS
0:43
virus at imune will continue more than a
0:45
decades worth of R&D by AGT focused on
0:48
developing Gene and cell therapy
0:50
Technologies aimed at curing HIV the new
0:53
spin out company will continue the
0:55
development of a GT1 103t
0:58
103t which success u f completed the
1:00
phase I repair trial restore potent
1:03
antiviral immune responses NCT
1:08
258 by showing positive safety results
1:11
in seven patients the phase ey trial
1:14
along with another sponsor initiated
1:16
follow on study named durable
1:18
anti-retroviral withdrawal initiative
1:23
5,529 342 showed active immune responses
1:27
to HIV up to 6 months after do dosing AG
1:32
gt13 T is a single do lentiviral based
1:36
autus Cell Therapy delivering gene
1:39
therapy modified HIV specific CD4 t-
1:42
cells to people with HIV ad immune
1:45
reasons that while HIV depletes the HIV
1:48
specific CD4 t- cell responsible for a
1:51
potent immune response forcing patients
1:53
onto lifelong anti-retroviral therapy
1:56
natural immune control of HIV could be
1:58
restored if the depleted cells are
2:00
replaced by durable te- cells are
2:02
replaced by durable tea cells AG
2:05
gt13 te is designed to induce the
2:08
exceptional control of viral replication
2:11
and intact immune responses without
2:14
anti-retroviral drugs shown by two
2:16
categories of people living with HIV I
2:19
controllers who can maintain
2:20
undetectable viral loads for at least 12
2:23
months despite not having started
2:25
anti-retroviral therapy and long-term
2:28
non-progressor individuals who are HIV
2:30
positive yet remain healthy for long
2:32
periods of time without
2:34
medications the potential of a gt13 t
2:38
and future plans by years's end ad
2:41
immune researchers plan to publish
2:43
additional data from a subsequent
2:44
analytic treatment Interruption ATI
2:49
5,540 40, 964 designed to assess the
2:54
Effy of a gt13 in patients after they
2:57
stopped taking anti-retroviral therapy
3:00
the ATI study was designed to generate
3:03
immunologic and viologic data in
3:05
patients who are not currently taking
3:07
typically prescribed anti-retroviral
3:08
medications for HIV AGT said in June
3:12
that this data set showed impressive
3:14
viral suppression with all participants
3:17
showing active immune responses to HIV
3:19
the data showed that more than half of
3:21
the participants achieved significant
3:24
suppression following finalization of
3:26
the study and peer review the company
3:29
said it intens to have the study results
3:31
published in a scientific journal Beyond
3:33
current treatments ad immune reasons
3:35
that a GT1 103t could help position as a
3:38
functional cure for HIV an option that
3:41
is currently unavailable among the 32
3:43
anti-retroviral drugs one
3:45
pharmacokinetic enhancer and 21 fixed do
3:48
combinations all approved by the FDA to
3:50
treat HIV AIDS in the four decades since
3:53
HIV was discovered if ad immune succeeds
3:57
it could disrupt a market for HIV
3:59
treatments valued between $22 5 C
4:02
billion and3 $1 billion last year but
4:05
with only low single digit growth
4:09
2030 as Jeff Galvin COO of Adam mune
4:13
stated the field is crowded with
4:16
treatments but it's not crowded with
4:17
cures we're the only cure attempt out
4:20
there that has our level of data safety
4:22
and Effy a now we don't have full
4:25
efficacy I don't want to overplay this
4:27
but the data is really exciting to
4:28
people in the know in virology and
4:31
Immunology within the HIV industry and
4:34
we've attracted a who's who to this
4:36
project and what they're telling me is
4:38
this looks like it can work the future
4:41
of AD imune and octone
4:43
1003 ad imune is swinging for the fences
4:46
aiming to go beyond what existing
4:48
treatments from companies like Gilead
4:50
and VI offer Galvin emphasized that the
4:53
goal is to develop a oneandone Cell
4:55
Therapy allowing people on lifelong
4:57
treatment drugs to potentially stop
4:59
taking them and forget about HIV
5:01
entirely as their immune system
5:03
naturally controls the virus ad immune
5:06
is committed to developing a GT 103t
5:09
through the regulatory phase the spin
5:11
out company believes that the data
5:13
justifies full focus and full funding to
5:15
maximize the chances of achieving a
5:17
one-time treatment the name ad immune
5:20
combines two key Concepts adding new
5:23
capacity to the human te- cell through
5:24
Gene and cell therapy and creating an
5:26
improved immune system to fight HIV
5:30
the recent phasi trial data showed that
5:32
a gt13 t generated immune responses in
5:36
all seven patients dosed with the
5:38
therapy the Persistence of a GT 103
5:41
modified te- cells and significant
5:43
increases in Gag specific CD4 and cd8 t-
5:46
cells were observed indicating a
5:48
promising direction for further
5:50
development adune is now developing the
5:53
protocol for a planned phase I trial of
5:56
gt13 t aiming to establish efficacy
5:59
level lels that could justify a pivotal
6:01
study and potential commercialization
6:03
the long-term Vision includes the
6:05
possibility of an HIV vaccine leveraging
6:08
gene therapy technology to induce
6:10
functional cure status in people living
6:13
HIV and that's it for today's video
6:16
thank you for joining us on this
6:17
informative Journey Don't forget to like
6:19
share and subscribe for more updates on
6:21
health awareness congratulations if
6:23
you're already subscribed you're among
6:25
the 1.5 who take their health seriously
6:29
if not hit that subscribe button now so
6:31
you won't miss our next video thank you
6:33
for watching Remember staying informed
6:36
is a crucial step in staying healthy
6:38
until we meet again stay healthy
